Medtronic plc MDT, the global leader in
medical technology, today announced U.S. Food and Drug Administration
(FDA) clearance of MiniMed(R) Connect. Designed to provide a mobile
connection to critical information for managing diabetes, MiniMed
Connect is the first product to enable people with diabetes to
discreetly and conveniently view their insulin pump and continuous
glucose monitor (CGM) data on a smartphone and provides remote
monitoring and text message notifications for their loved ones. It also
gives healthcare teams more convenient access to more comprehensive
patient data so they can adjust their patients' care plans. The new
product clearance was announced from the American Diabetes Association
75th Scientific Sessions in Boston and will be on display at Booth #437.
MiniMed Connect consists of a small device that easily fits on a
keychain or in a pocket, a smartphone app for the person with diabetes,
and a web display on desktop or mobile devices for their care partners.
The MiniMed Connect device securely transmits pump and sensor glucose
data from the patient's MiniMed insulin pump to the app and web display,
which shows real-time sensor glucose and insulin information on the
phone or any Internet-enabled device anytime, anywhere. The system also
delivers preset text notifications to loved ones when the person with
diabetes' glucose values go too high or too low, or when an alarm on the
pump isn't cleared, providing greater peace of mind for care partners.
In addition, MiniMed Connect provides healthcare teams with more
comprehensive data, and with more convenient access to their patients'
diabetes data so they can adjust care plans.
"Engagement from people with diabetes, loved ones and healthcare
providers is key to living well with diabetes. With MiniMed Connect, the
entire care team can have access to critical diabetes data to inform the
decisions that help people have better outcomes," said Annette
Brüls, vice president and general manager, Diabetes Services and
Solutions at Medtronic. "MiniMed Connect is another step in our broader
strategy to be a holistic diabetes management company. The Connect
platform represents how we will use leadership technologies, data and
informatics to enable better therapy decision making and care for people
with diabetes. Our hope is that this will make it easier for more people
to manage their disease and optimize their therapy so they can achieve
greater freedom and better health."
The MiniMed Connect remote web display will be available with iOS,
Android, or any other Internet-enabled devices. The related smartphone
app will initially be available with iOS devices. Samsung is working
with Medtronic to also develop an app for Android and optimized
experiences on Samsung mobile devices.
MiniMed Connect, which is a secondary display device, is compatible with
both the MiniMed(R) 530G system and the MiniMed(R) Revel(TM) system.
The product is expected to be available this fall. People with diabetes
can visit www.medtronicdiabetes.com/minimed-connect to sign up to be
notified when the product is available.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in